Acquisition-related liabilities

Name: Rigel Pharmaceuticals Acquisition-related liabilities by Products & Services
Creator: OpenCapital
License: https://www.opencapital.sh/terms

Rigel Pharmaceuticals·Products & Services·1 segment·Rolls up to Contingent liabilities

Breakdown

Segment	Q3 '24	Q4 '24	Q2 '25	Q3 '25	Q4 '25	Q1 '26
GAVRETO (pralsetinib)	$5M	$5M	$5M	$5M	$5M	$5M
Total	$5M	$0	$5M	$5M	$5M	$5M

Segments

GAVRETO (pralsetinib)View metric